Pertschuk L P, Eisenberg K B, Carter A C, Feldman J G
Cancer. 1985 Apr 1;55(7):1513-8. doi: 10.1002/1097-0142(19850401)55:7<1513::aid-cncr2820550717>3.0.co;2-4.
Breast cancer specimens from 114 patients were assayed for the presence of estrogen receptors (ER) utilizing highly specific, monoclonal antiestrophilin antibodies and the peroxidase-antiperoxidase technique. Results were compared with conventional ER determinations by the dextran-coated charcoal method (DCC) and were in agreement as to positivity and negativity in 86%. Semiquantified immunocytologic assay results were in accord with the level of ER as measured by DCC in 66%. The tumors studied included 43 from patients with Stage IV disease where clinical response to hormonal manipulation was known. In the latter group, the immunohistologic method had a sensitivity similar to that of DCC but showed a superior positive predictive value and a significantly better specificity. These results indicate that this new method is a valuable laboratory tool, enabling prediction of hormone responsiveness in advanced mammary carcinoma and capable of performance at the community hospital level.
利用高度特异性的单克隆抗雌激素受体蛋白抗体和过氧化物酶-抗过氧化物酶技术，对114例患者的乳腺癌标本进行雌激素受体（ER）检测。将结果与采用葡聚糖包被活性炭法（DCC）的传统ER检测结果进行比较，二者在阳性和阴性结果上的一致率为86%。半定量免疫细胞检测结果与DCC法测定的ER水平在66%的病例中相符。所研究的肿瘤包括43例来自IV期疾病患者，已知其对激素治疗的临床反应。在后一组中，免疫组织化学方法的敏感性与DCC法相似，但显示出更高的阳性预测值和显著更好的特异性。这些结果表明，这种新方法是一种有价值的实验室工具，能够预测晚期乳腺癌的激素反应性，并且能够在社区医院层面开展。
